Welcome Guest
Home » Reports » Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017 - 2030

Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017 - 2030

Published: May 17, 2017
Pages: 425
Product Code: RA10081
License Type :  (Learn More)

Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors that influence the disease origin, propagation, spread (metastasis) and relapse. In 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer. The high cancer mortality rate is primarily due to delay in detection of the disease. Therefore, in addition to satisfying the unmet market need for advanced and efficient treatment interventions, early cancer diagnosis and screening form an important component of disease prevention and cure. Early diagnosis increases the survival rate that is unlikely to happen if the disease is identified at an advanced stage.

 

Invasive cancer diagnostic methods such as tissue biopsies have been the gold standard to determine the clinico-pathological characteristics of cancer tissues for many years. The procedure is not only cost-intensive but is also a traumatic experience for the patients. Additionally, endoscopies such as colonoscopy, gastroscopy and laparoscopy are also employed for cancer diagnosis. However, biopsies and endoscopies only offer insights of the disease state at a single point of time. They are unable to measure the disease progression or monitor the effects of the administered therapy over the treatment period. Therefore, the current cancer diagnostics market faces a pressing need for more accurate non-invasive methods of diagnosis to ensure better patient care.

 

There are several advanced approaches that are not only non-invasive / minimally invasive but also outweigh the limitations posed by invasive diagnostic procedures. Liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool that analyzes biofluids (blood, urine or plasma) to detect rare cells and biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs) or exosomes. Moreover, liquid biopsies are capable of not only analyzing the tumor state at the time of sample extraction but can also monitor and track changes in tumor genetics over the course of treatment. In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies that exploit skin lesions, bronchial fluid and exhaled breath as samples to trace signatures of cancer. These tests use gene expression profiles, biomarker analysis, volatile organic compound detection and other advanced techniques of molecular genetics to identify a particular cancer indication.

 

These non-invasive diagnostic techniques, backed by patient success stories, awareness and the availability of successful clinical validation data for several cancer indications, hold a significant promise and are anticipated to replace the existing invasive diagnostic tools in the coming few years. In fact, social media platforms, such as Twitter, have witnessed an increasing volume of tweets over the years. Between 2010 and 2016, we were able to identify over 7,000 tweets; this clearly indicates an upsurge in the popularity of these non-invasive tests in the given time period. With liquid biopsy on the forefront, the overall non-invasive cancer diagnostics market is likely to receive a significant boost in the near future.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030’ report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. The market is characterized by the presence of several companies that have proprietary technologies / platforms for either isolation / enrichment / enumeration of CTCs or for molecular characterization / sequencing of the genetic material extracted from the CTCs / exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, and patient and recurrence monitoring of different cancer indications. Such kits are likely to transform the cancer diagnostics market with many commercial success stories in the near future.

 

The market is primarily led by start-ups / small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences,  iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomics Laboratories. In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and Thermo Fisher Scientific.

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market. Amongst other elements, the report provides information on:

  • The overall landscape of liquid biopsies and other novel non-invasive diagnostic tests with respect to the stage of development, type of markers (CTCs / ctNA / exosomes), test sample source (blood / urine / others), indications and type of application (early diagnosis / recurrence monitoring / patient monitoring). Additionally, the market overview highlights the geographical distribution and coverage of the tests across the globe, depicting the activity of this domain in different regions of the world.
  • Comprehensive profiles of the popular tests and systems highlighting details on development status, specifications and advantages, clinical information, and related collaborations. Additionally, we have provided detailed profiles of the key players involved in the domain.
  • The impact of venture capital funding in this area. It is important to mention that since the industry has witnessed the emergence of several start-ups, funding is a key enabler that is likely to drive both innovation and product development in the coming years.
  • An elaborate valuation analysis of start-ups and small players that are involved in the liquid biopsy domain. We built a multi-variable dependent valuation model to estimate the current valuation of a number of companies focused in this domain.
  • The emerging trends and the popularity of liquid biopsy on social media platforms, such as Twitter, over the last few years. The volume of tweets has witnessed an increasing trend in the last six years, influenced by the approval and launch of several liquid biopsy tests in the market.
  • The competitive landscape of the players involved in the space. This is represented as an illustrative bubble analysis, which is based on parameters such as the liquid biopsy portfolio of a company, its number of employees and geographical coverage of the tests.
  • Contribution of the other non-invasive cancer diagnostics market, taking into account the number of tests and the sales registered by the marketed tests.

 

In addition, we have provided a comprehensive market estimation to determine the global evolution of the liquid biopsy market. This has been done by evaluating the likely success of key applications of early diagnosis, recurrence monitoring and patient monitoring. We have included insights on the likely regional evolution of the market covering US, EU5 and rest of the world. In addition, we have estimated the likely contribution of different target patient populations to the global market; this covered key indications including (in alphabetical order) bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. Further, we segmented the market by the type of markers (CTCs, ctNAs, exosomes) and the sample source (blood, urine, saliva) used in different liquid biopsies. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the time period 2017-2030. The conservative, base and optimistic scenarios represent three different tracks of the industry’s evolution. The research, analysis and insights presented in this report are backed by the deep understanding of key insights gathered from both secondary and primary research.

 

Our opinions and insights presented in this study were influenced by discussions that we conducted with several experts in this area. These included contributions from (in alphabetical order of companies) Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience) and Jake Micallef (Chief Scientific Officer, VolitionRx). All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

 

Example Highlights

  1. We identified over 110 liquid biopsy tests; of these, 60% of the tests are currently available for patients while the remaining are either available for research use only (RUO) or are under development. Further, of the total tests, 36% detect the presence of ctDNA in the sample, nearly 41% detect CTCs and 4% validate the presence of exosomes. Close to 19% of the liquid biopsy tests identify the presence of multiple / other markers.
  2. Seven liquid biopsy tests are being explored for use as companion diagnostics. Many partnerships have been inked to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between BMS and GRAIL (2017), Merck and Sysmex Inostics (2016), Biocept and Baylor College of Medicine (2015), QIAGEN and Tokai Pharmaceuticals (2015), ANGLE and MD Anderson Cancer Center (2015), and AstraZeneca and QIAGEN (2015).
  3. Considering the future potential of these diagnostic kits and systems, several investors have made substantial capital commitment to drive future development. We identified approximately 196 funding instances amounting to capital investments (equity / debt / grants) of over USD 3.8 billion between 2011 and 2017; these investments were made either directly or indirectly to support the development of liquid biopsy products. In 2016 alone, driven by increased venture capital activity, amount worth USD 770 million was invested in different companies.
  4. With the rising activity in the field of cancer diagnostics, pharmaceutical players have been keen to explore the acquisition opportunities in this domain. In the Roots Analysis proprietary valuation analysis of over 40 start-ups / small companies, we identified nine companies that are likely to achieve valuation of over USD 500 million.
  5. The market, primarily driven by the sales generated by liquid biopsy tests, is anticipated to register a growth rate of 19% between 2017 and 2030. The current market is dominated by the tests that offer patient monitoring (63% share). Specifically, catering to the high unmet need for timely treatment, the share of early diagnosis is likely to increase from 20% in 2017 to over 40% by 2030.
  6. Among specific indications, we believe that prostate cancer is likely to capture the largest share of the market (~15%). Subsequently, owing to the large target patient population, breast cancer is likely to capture a share of 14% by 2030. In addition, lung cancer is also likely to capture a significant market share of 12% by 2030. It is worth highlighting that, despite the low prevalence of lung cancer, the demand of liquid biopsies is significantly high as tissue biopsy is extremely difficult in case of lungs.
  7. With regard to the geographical activity, in 2017, the US is likely to capture the maximum share (43%) followed by EU5 (34%) and Rest of the World (RoW, 23%). The overall trend is unlikely to change significantly in 2030; however, regions in RoW are likely to occupy a larger share in 2030 (29%). It is important to highlight that, within RoW, Asian countries such as China, India, Japan, have several developers and distributors of liquid biopsy tests, demonstrating an elevating activity within these regions.

 

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming 10-15 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

 

Chapter 3 provides a general introduction to cancer statistics and the global burden of the disease. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

 

Chapter 4 discusses, in detail, the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

 

Chapter 5 provides a holistic view of the liquid biopsy market. It lists the liquid biopsy tests, technologies and systems. In addition, the chapter includes a detailed analysis of the liquid biopsy tests based on the development stage (available for patients / RUO / under development), sample type (blood / plasma / urine / multiple), type of markers detected (CTCs / ctNA (DNA) / exosomes / multiple / others), indication and type of application (early detection / patient monitoring / recurrence monitoring).

 

Chapter 6 offers an illustrative bubble analysis representing the competitive landscape of the players involved in the space, based on their liquid biopsy portfolio, number of employees and geographical coverage. In addition, it presents a Venn diagram depicting the distribution of liquid biopsy products across different application areas. The chapter elucidates the emerging trends and the popularity of liquid biopsy on social media platforms, such as Twitter, over the last few years.

 

Chapter 7 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages, and the related challenges. In addition, we have provided profiles of several liquid biopsy products and technologies. These products belong to those companies that were identified as active players in the bubble analysis presented in Chapter 6. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

 

Chapter 8 presents details on the investments and grants received by companies working in the field of liquid biopsy. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.

 

Chapter 9 features a comprehensive valuation analysis of the companies that are developing liquid biopsy tests / technologies / systems / platforms / instruments. The chapter provides insights based on a multi-variable dependent valuation model. The model is based on the future potential of the companies’ uniqueness, their current popularity, funding received, year of establishment and the employed workforce.

 

Chapter 10 provides detailed company profiles of the leading players that are involved in the development of liquid biopsy tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio (technical specifications and clinical information) and recent collaborations.

 

Chapter 11 provides an overview of the other non-invasive diagnostics for oncology. It highlights different diagnostics tests, including non-blood based biomarker detection tests (saliva-based biomarker detection, stool-based metabolic biomarker detection, skin-based biomarker detection, semen-based biomarker detection and urine based biomarker detection), DNA methylation detection test, fecal occult blood test and fecal immunochemical test, MicroRNA (miRNA) based test, pigmented lesion assay, stool DNA (sDNA) testing, and Volatile Organic Compound (VOC) detection test. The diagnostic procedures discussed in this chapter are backed up by several examples. In addition, the chapter illustrates a detailed analysis on the survey conducted for gaining a deeper understanding on the nature of products and services offered by the companies.

 

Chapter 12 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters that are likely to influence the evolution of liquid biopsy market. It features detailed insights on the likely market evolution for across different application areas such as early diagnosis, patient monitoring and recurrence monitoring. Additionally, the chapter presents a detailed market segmentation by the key indications, types of markers (CTCs, ctNAs, exosomes) and types of samples (blood, urine, saliva). The chapter also highlights the likely distribution of the market across the US, EU5 and RoW (including Asia) regions. We have also presented an informed view on the contribution of the other non-invasive tests in the overall non-invasive cancer diagnostics market.

 

Chapter 13 summarizes the overall report. In this chapter, we have listed the key takeaways and have provided our independent opinion based on the research and analysis described in previous chapters.

 

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience) and Jake Micallef (Chief Scientific Officer, VolitionRx)

 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.


 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Detection in Cancer
3.4. Detecting Cancer: Screening vs. Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
3.7. Costs and Benefits Associated with Non-Invasive Tests
 
4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated PET-CT Scan
4.2.6. Ultrasound
4.2.7. Barium Enema
4.3. Screening Assays
4.3.1. Papanicolaou Test (Pap Test) and Human Papilloma Virus Test (HPV Test)
4.3.2. Tumor Marker Test
4.3.3. Fecal Occult Blood Tests (FOBT)
4.3.4. Digital Rectal Exam (DRE)
4.3.5. Multigated Acquisition (MUGA) Scan
4.4. Advanced Non-Invasive Approaches
4.4.1. Liquid Biopsy
4.4.2. Cytogenetic / Gene Expression Studies
4.4.3. Molecular Signature Based Non-Invasive Methods
4.4.4. Saliva-Based Oral Cancer Diagnostics
4.4.5. Vital Staining
4.4.6. Optical Biopsy
4.4.7. Other Techniques
 
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy: Development Landscape
5.2.1. Liquid Biopsy Tests: Distribution by Development Stage
5.2.2. Liquid Biopsy Tests: Distribution by Sample Type
5.2.3. Liquid Biopsy Tests: Distribution by Type of Markers Detected
5.2.4. Liquid Biopsy Tests: Distribution by Indication
5.2.5. Liquid Biopsy Tests: Distribution by Type of Application
5.2.6. Liquid Biopsy Tests: Distribution by Geographical Coverage
5.2.7. Liquid Biopsy Tests: Distribution by Leading Players
5.3. Liquid Biopsy: Technologies, Platforms, Systems and Instruments
 
6. LIQUID BIOPSY MARKET: KEY INSIGHTS
6.1. Chapter Overview
6.2. Liquid Biopsy Tests: Competitive Landscape of Developers
6.3. Liquid Biopsy Tests: Distribution by Application and Target Indications
6.4. Emerging Trends on Non-Invasive Cancer Diagnostics on Social Media
6.4.1. Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
6.4.2. Non-Invasive Cancer Diagnostics:  Twitter Word Cloud (2010, 2012, 2014, 2016)
6.4.3. Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
6.4.4. Non-Invasive Cancer Diagnostics: Twitter Trends for Samples Types (2010-2016)
 
7. LIQUID BIOPSY: DETAILED OUTLOOK
7.1. Chapter Overview
7.2. Non-Invasive Methods Over Biopsies for Detection of Cancer
7.3. Circulating Biomarkers for Cancer
7.3.1. Circulating Tumor Cells (CTCs) 
7.3.1.1. Advantages Associated with the Use of CTCs
7.3.1.2. Challenges Associated with the Use of CTCs
7.3.2. Circulating Tumor DNA (ctDNA)
7.3.3. Exosomes
 
7.4. Liquid Biopsy Based Tests and Systems
7.4.1. BioFluidica CTC Isolation Technology, CTC Analysis System and Test, BioFluidica / Roche
7.4.1.1. Overview
7.4.1.2. Specifications and Advantages
7.4.1.3. Clinical Information
7.4.1.4. Collaborations
 
7.4.2. CancerIntercept™ Detect and CancerIntercept™ Monitor, Pathway Genomics
7.4.2.1. Overview
7.4.2.2. Specifications and Advantages
7.4.2.3. Clinical Information
7.4.2.4. Collaborations
 
7.4.3. Cancertrack, Datar Genetics
7.4.3.1. Overview
7.4.3.2. Specifications and Advantages
7.4.3.3. Clinical Information
7.4.3.4. Collaborations
 
7.4.4. CellMax-LBx Liquid Biopsy and CellMax-CRC Colorectal Cancer Blood Test, CellMax Life
7.4.4.1. Overview
7.4.4.2. Specifications and Advantages
7.4.4.3. Clinical Information
7.4.4.4. Collaborations
 
7.4.5. CELLSEARCH® System and CELLSEARCH® CTC Test, Menarini Silicon Biosystems
7.4.5.1. Overview
7.4.5.2. Specifications and Advantages
7.4.5.3. Clinical Information
7.4.5.4. Collaborations
 
7.4.6. cobas® EGFR Mutation Test v2, Roche
7.4.6.1. Overview
7.4.6.2. Specifications and Advantages
7.4.6.3. Clinical Information
7.4.6.4. Collaborations
 
7.4.7. LiquidBiopsy® Rare Cell Isolation Platform, ClearID® Total Insight Breast Cancer, ClearID® Lung Cancer and Clear ID® Melanoma, Cynvenio Biosystems
7.4.7.1. Overview
7.4.7.2. Specifications and Advantages
7.4.7.3. Clinical Information
7.4.7.4. Collaborations
 
7.4.8. Oncocount, Oncotrace, Oncotrial and Metastat, R.G.C.C. Group
7.4.8.1. Overview
7.4.8.2. Specifications and Advantages
7.4.8.3. Clinical Information
 
7.4.9. OncoBEAM™ CRC RAS Kit, Sysmex Inostics / Merck
7.4.9.1. Overview
7.4.9.2. Specifications and Advantages
7.4.9.3. Clinical Information
7.4.9.4. Collaborations
 
7.4.10. OnTarget™ Assay, Boreal Genomics
7.4.10.1. Overview
7.4.10.2. Specifications and Advantages
7.4.10.3. Clinical Information
7.4.10.4. Collaborations
 
7.4.11. PrediSeq-Prostate and PrediSeq-Lung, Predicine
7.4.11.1. Overview
7.4.11.2. Specifications and Advantages
7.4.11.3. Clinical Information
7.4.11.4. Collaborations
 
7.4.12. SelectMDx™, MDxHealth
7.4.12.1. Overview
7.4.12.2. Specifications and Advantages
7.4.12.3. Clinical Information
7.4.12.4. Collaborations
 
7.4.13. ViewRNA™ CTC Platform and Assay, Affymetrix
7.4.13.1. Overview
7.4.13.2. Specifications and Advantages
7.4.13.3. Collaborations
 
7.4.14. Velox™, IVDiagnostics
7.4.14.1. Overview
7.4.14.2. Collaborations
 
7.4.15. ApoStream® System and Technology, ApoCell
7.4.15.1. Overview
7.4.15.2. Specifications and Advantages
7.4.15.3. Clinical Information
7.4.15.4. Collaborations
 
7.4.16. IsoPic™, iCellate Medical
7.4.16.1. Overview
7.4.16.2. Specifications and Advantages
7.4.16.3. Clinical Information
7.4.16.4. Collaborations
 
7.4.17. Parsortix™ System, ANGLE
7.4.17.1. Overview
7.4.17.2. Specifications and Advantages
7.4.17.3. Clinical Information
7.4.17.4. Collaborations
 
7.5. Companion Liquid Biopsies: Recent Developments
7.5.1. Biocept and Baylor College of Medicine
7.5.2. Tokai Pharmaceuticals and QIAGEN
7.5.3. ANGLE and MD Anderson Cancer Center
7.5.4. AstraZeneca and QIAGEN
7.5.5. Sysmex Inostics and Bayer Healthcare
 
8. VENTURE CAPITAL FUNDING
8.1. Chapter Overview
8.2. Types of Funding
8.3. Liquid Biopsy Market: Funding Instances, 2011-2017
8.4. Liquid Biopsy Market: Distribution by Year
8.5. Liquid Biopsy Market: Distribution of Type of Model
8.6. Leading Players: Distribution by Funding Instances
 
9. COMPANY VALUATION ANALYSIS
9.1. Chapter Overview
9.2. Company Valuation: Methodology
9.3. Company Valuation: Categorization by Multiple Parameters
9.3.1. Categorization by Google Hits Score
9.3.2. Categorization by Awards Score
9.3.3. Categorization by Twitter Score
9.3.4. Categorization by Twitter Followers Score
9.3.5. Categorization by Number of Products
9.3.6. Categorization by Uniqueness Score
9.3.7. Categorization by Weighted Average Score
9.4. Company Valuation: Roots Analysis Proprietary Scores
 
10. LIQUID BIOPSY: KEY PLAYERS
10.1. Chapter Overview
10.2. Biocartis
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.3.1. Idylla™ ctBRAF Mutation Assay (RUO)
10.2.3.2. Idylla™ ctKRAS Mutation Assay
10.2.3.3. Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO)
10.2.4. Collaborations
 
10.3. Biocept
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.3.1. Target Selector™ Breast Cancer Test
10.3.3.2. Target Selector™ Lung Cancer Test
10.3.3.3. Target Selector™ Immuno-Oncology PD-L1 Test
10.3.3.4. Target Selector™ Gastric Cancer Test
10.3.3.5. Target Selector™ Colorectal Cancer Test
10.3.3.6. Target Selector™ Prostate Cancer Test
10.3.3.7. Target Selector™ Melanoma Test
10.3.4. Collaborations
 
10.4. Biodesix
10.4.1. Company Overview
10.4.2. Financial Information
10.4.3. Product Portfolio
10.4.3.1. GeneStrat®
10.4.3.2. VeriStrat®
10.4.4. Collaborations
 
10.5. Exosome Diagnostics
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Product Portfolio
10.5.3.1. ExoDx™ Prostate (IntelliScore) 
10.5.3.2. ExoDx™ Lung (ALK)
10.5.3.3. ExoDx™ Lung (EGFR/T790M)
10.5.3.4. ExoDx™ Solid Tumor
10.5.4. Collaborations
 
10.6. Genomic Health
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.3.1. Oncotype SEQ™ Liquid Select
10.6.4. Collaborations
 
10.7. Guardant Health
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Product Portfolio
10.7.3.1. Guardant360™
10.7.4. Collaborations
 
10.8. NeoGenomics Laboratories
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.3.1. NeoLAB™ HEME
10.8.3.2. NeoLAB™ Solid Tumor Monitor (NeoLAB SOLID TUMOR)
10.8.3.3. NeoLAB™ Prostate
10.8.3.4. NeoLAB™ EGFR T790M Liquid Biopsy
10.8.4. Clinical Information
10.8.5. Collaborations
 
10.9. Personal Genome Diagnostics (PGDx)
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Product Portfolio
10.9.3.1. MetDETECT™
10.9.3.2. PlasmaSELECT™ R 64
10.9.3.3. LungSELECT™
10.9.4. Collaborations
 
10.10. QIAGEN
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Portfolio
10.10.3.1. AdnaTest Technology (Acquired from AdnaGen)
10.10.3.2. therascreen® EGFR RGQ PCR Kit
10.10.3.3. Sample Preparation Kits
10.10.4. Collaborations
 
10.11. Transgenomic
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Portfolio
10.11.3.1. MX-ICP CRC Analysis
10.11.3.2. MX-ICP Melanoma Analysis
10.11.3.3. MX-ICP NSCLC Analysis
10.11.4. Collaborations
 
10.12. Trovagene
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Portfolio
10.12.3.1. Trovera™ BRAF Mutation Detection
10.12.3.2. Trovera™ EGFR Mutation Detection
10.12.3.3. KRAS Mutation Detection
10.12.3.4. HPV HR Detection Test
10.12.4 Collaborations
 
11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood Based Biomarker Detection Tests
11.3. DNA Methylation Detection Tests
11.4. Fecal Occult Blood Test (FOBT) AND Fecal Immunochemical Test (FIT)
11.5. MicroRNA (miRNA) Based Test
11.6. Pigmented Lesion Assay
11.7. Stool DNA (sDNA) Testing
11.8. Volatile Organic Compound (VOC) Detection Test
11.9. Other Non-Invasive Cancer Diagnostics: Market Landscape
11.10. Other Non-Invasive Cancer Diagnostics: Survey Analysis
11.10.1. Survey Analysis: Seniority Level of Respondents
11.10.2. Survey Analysis: Type of Product Portfolio
11.10.3. Survey Analysis: Types of Products / Services Offered
11.10.4. Survey Analysis: Type of Application
11.10.5. Survey Analysis: Availability of the Products
11.10.6. Survey Analysis: Likely Market Size
 
12. MARKET SIZING AND FORECAST
12.1. Chapter Overview
12.2. Forecast Assumptions and Methodology
12.3. Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
12.3.1. Liquid Biopsy Market Forecast, 2017-2030
12.3.1.1. Liquid Biopsy Market Forecast: Distribution by Application
12.3.1.2. Liquid Biopsy Market Forecast: Distribution by Indication
12.3.1.3. Liquid Biopsy Market Forecast: Distribution by Type of Marker
12.3.1.4. Liquid Biopsy Market Forecast: Distribution by Type of Sample
12.3.1.5. Liquid Biopsy Market Forecast: Distribution by Geography
12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
 
13. CONCLUSION
13.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
13.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
13.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
13.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
13.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
13.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
13.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
13.8. Primarily Led by Liquid Biopsy, The Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market
 
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Burkhard Jansen, MD, Chief Medical Officer, DermTech 
14.3. Frank Szczepanski, President and CEO, IVDiagnostics
14.4. Riccardo Razzini, Sales and Marketing Manager, LCM Genect
14.5. Nathalie Bernard, Marketing Director, OncoDNA
14.6. Abizar Lakdawalla, Founder, ProXeom
14.7. Mark Li, CEO, Resolution Bioscience
14.8. Christer Ericsson, Chief Scientific Officer, iCellate Medical
14.9. Philippe Nore, CEO and Co-founder, MiNDERA
14.10. Jake Micallef, Chief Scientific Officer, VolitionRx
 
15. APPENDIX 1:  TABULATED DATA
 
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
 
 
Figure 3.1 Worldwide Incidence of Cancer: Distribution by Type 
 
Figure 3.2 Lung Cancer: Estimated New Cases in 2016 (In Thousands) 
 
Figure 3.3 Breast Cancer: Estimated New Cases in 2016 (In Thousands) 
 
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2016 (In Thousands)
 
Figure 3.5 Factors Determining Useful Cancer Screening
 
Figure 3.6 Conventional Cancer Diagnosis Methods
 
Figure 3.7 Disadvantages of Conventional Cancer Diagnosis Methods
 
Figure 3.8 Traditional Biopsy: Process Flow
 
Figure 3.9 Non-Invasive Biopsy: Process Flow
 
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
 
Figure 4.2 Types of Diagnostic Imaging
 
Figure 4.3 Types of Screening Assays
 
Figure 4.4 Types of Advanced Non-Invasive Approaches
 
Figure 5.1 Liquid Biopsy Tests: Distribution by Development Stage
 
Figure 5.2 Liquid Biopsy Tests: Distribution by Sample Type
 
Figure 5.3 Liquid Biopsy Tests: Distribution by Type of Markers Detected
 
Figure 5.4 Liquid Biopsy Tests: Distribution by Indication
 
Figure 5.5 Liquid Biopsy Tests: Distribution by Type of Application
 
Figure 5.6 Liquid Biopsy Tests: Distribution by Leading Players
 
Figure 6.1 Liquid Biopsy Competitive Landscape: Established Players
 
Figure 6.2 Liquid Biopsy Competitive Landscape: Mid-Sized Players
 
Figure 6.3 Liquid Biopsy Competitive Landscape: Start-ups
 
Figure 6.4 Liquid Biopsy Tests (Available for Patients): Distribution by Application and Target Indications
 
Figure 6.5 Liquid Biopsy Tests (Available for RUO / Under Development): Distribution by Application and Target Indications
 
Figure 6.6 Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
 
Figure 6.7 Non-Invasive Cancer Diagnostics: Twitter World Cloud (2010, 2012, 2014, 2016)
 
Figure 6.8 Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
 
Figure 6.9 Non-Invasive Cancer Diagnostics: Twitter Trends for Sample Type (2010-2016)
 
Figure 7.1 Circulating Biomarkers for Cancer Detection
 
Figure 7.2 BioFluidica CTC Isolation System: Steps of Operation
 
Figure 7.3 BioFluidica CTC Isolation System: Advantages
 
Figure 7.4 CellMax’s Liquid Biopsy: Steps of Operation
 
Figure 7.5 CELLSEARCH® System: Steps of Operation
 
Figure 7.6 cobas® EGFR Mutation Test v2: Steps of Operation
 
Figure 7.7 LiquidBiopsy® Rare Cell Isolation Platform: Steps of Operation
 
Figure 7.8 LiquidBiopsy® Rare Cell Isolation Platform and Ion Torrent™ PGM Workflow Components
 
Figure 7.9 OnTarget™ Assay: Steps of Operation
 
Figure 7.10 PrediSeq: Steps of Operation
 
Figure 7.11 ViewRNA™ CTC Platform: Steps of Operation
 
Figure 7.12 Apostream® Technology: Advantages
 
Figure 7.13 IsoPic™ Instrument: Steps of Operation
 
Figure 7.14 Parsortix™ System: Steps of Operation
 
Figure 8.1 Liquid Biopsy Market: Cumulative Funding Instances, 2011-2017
 
Figure 8.2 Liquid Biopsy Market: Cumulative Funding Amount, 2011-2017 (USD Billion)
 
Figure 8.3 Liquid Biopsy Market: Distribution by Type of Funding Instances, 2011-2017
 
Figure 8.4 Liquid Biopsy Market: Distribution by Total Amount Invested, 2011-2017 (USD Billion)
 
Figure 8.5 Liquid Biopsy Market: Distribution by Amount Invested and Type of Funding (USD Billion) 
 
Figure 8.6 Leading Players: Distribution by Number of Funding Instances
 
Figure 9.1 Company Valuation Analysis: A/F Ratio, Input Dataset
 
Figure 9.2 Company Valuation Analysis: A/Y Ratio, Input Dataset
 
Figure 9.3 Company Valuation Analysis: A/E Ratio, Input Dataset
 
Figure 9.4 Company Valuation Analysis: Categorization by Google Hits Score
 
Figure 9.5 Company Valuation Analysis: Categorization by Awards Score
 
Figure 9.6 Company Valuation Analysis: Categorization by Tweets Score
 
Figure 9.7 Company Valuation Analysis: Categorization by Twitter Followers Score
 
Figure 9.8 Company Valuation Analysis: Categorization by Number of Products
 
Figure 9.9 Company Valuation Analysis: Categorization by Uniqueness Score
 
Figure 9.10 Company Valuation Analysis: Categorization by Weighted Average Score
 
Figure 9.11 Company Valuation Analysis: Unicorns in Liquid Biopsy
 
Figure 10.1 Biocartis: Annual Revenues, 2012-2016 (EUR Million)
 
Figure 10.2 Idylla™: Steps of Operation
 
Figure 10.3 Biocept: Annual Revenues, 2012-2016 (USD Million)
 
Figure 10.4 Biodesix Lung Reflex Test: Steps of Operation
 
Figure 10.5 GeneStrat®: Clinical Validation Data
 
Figure 10.6 Genomic Health: Annual Revenues, 2010-2016 (USD Million)
 
Figure 10.7 Guardant360™: Steps of Operation
 
Figure 10.8 NeoGenomics Laboratory: Annual Revenues, 2010-2016 (USD Million)
 
Figure 10.9 NeoLAB™ Prostate: Steps of Operation
 
Figure 10.10 PlasmaSELECT™ R64: Steps of Operations
 
Figure 10.11 QIAGEN: Annual Revenues, 2010–2016 (USD Billion)
 
Figure 10.12 QIAGEN Sales, 2016: Distribution by Business Segments 
 
Figure 10.13 Transgenomic: Annual Revenues, 2010 – Q1-Q3 2016 (USD Million) 
 
Figure 10.14 ICEme Kit: Steps of Operation
 
Figure 10.15 Trovagene: Annual Revenues, 2010–2016 (USD Million)
 
Figure 11.1 Survey Analysis: Distribution by Geography
 
Figure 11.2 Survey Analysis: Seniority Levels of Respondents
 
Figure 11.3 Survey Analysis: Distribution by Type of Product Portfolio
 
Figure 11.4 Survey Analysis: Distribution by Type of Products / Services Offered
 
Figure 11.5 Survey Analysis: Distribution by Type of Application
 
Figure 11.6 Survey Analysis: Distribution by Availability of the Products
 
Figure 11.7 Survey Analysis: Likely Liquid Biopsy Market Size (2030)
 
Figure 11.8 Survey Analysis: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
 
Figure 12.1 Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
 
Figure 12.2 Liquid Biopsy Market (2017-2030): Base Scenario (USD Billion)
 
Figure 12.3 Liquid Biopsy Market: Share by Application (USD Billion, %)
 
Figure 12.4 Liquid Biopsy Market: Share by Indication (%)
 
Figure 12.5 Liquid Biopsy Market: Share by Type of Marker (%)
 
Figure 12.6 Liquid Biopsy Market: Share by Type of Sample (%)
 
Figure 12.7 Liquid Biopsy Market: Share by Geography (%)
 
Figure 12.8 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
 
Figure 13.1 Non-Invasive Cancer Diagnostics Market (USD Billion), 2017, 2023 and 2030
 
 
 
Table 3.1  Survival on Early Diagnosis of Cancer
 
Table 3.2  Cost of Biopsy for Different Cancer Indications (in USD)
 
Table 3.3 Common Endoscopic Procedures
 
Table 4.1 Examples of Tumor Markers
 
Table 5.1 Liquid Biopsy Tests: Development Landscape
 
Table 5.2 Liquid Biopsy Tests: Distribution by Type of Application
 
Table 5.3 Liquid Biopsy Tests: Distribution by Geographical Coverage 
 
Table 5.4 Liquid Biopsy: Technologies 
 
Table 5.5 Liquid Biopsy: Systems and Instruments
 
Table 7.1 Liquid Biopsy: Tests Profiled
 
Table 7.2 Liquid Biopsy: Systems / Technologies Profiled
 
Table 7.3 Comparison of Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
 
Table 7.4 Cancertrack: Biomarkers Detected
 
Table 7.5 SMSEQ™ Platform: Genes Detected
 
Table 7.6 CellMax Life: Publications
 
Table 7.7 CellMax Life: Posters / Presentations at Different Conferences
 
Table 7.8 CELLSEARCH® CTC Test: Cut-offs for Disease Prognosis
 
Table 7.9 CELLSEARCH® CTC Test: Publications
 
Table 7.10 cobas® EGFR Mutation Test v2: Publications
 
Table 7.11 LiquidBiopsy® Rare Cell Isolation: Specifications
 
Table 7.12 Cynvenio Biosystems: Publications
 
Table 7.13 Cynvenio Biosystems: Posters / Presentations at Different Conferences
 
Table 7.14 Metastat: Site Specific Biomarkers
 
Table 7.15 R.G.C.C. Group: Publications
 
Table 7.16 R.G.C.C. Group: Posters at Different Conferences
 
Table 7.17 R.G.C.C. Group: Presentations at Different Conferences
 
Table 7.18 BEAMing Technology: Publications
 
Table 7.19 BEAMing Technology: Posters / Presentations at Different Conferences
 
Table 7.20 PrediSeq: Gene Panel
 
Table 7.21 ViewRNA™ CTC Kits: Key Features
 
Table 7.22 Velox™: Potential Indications
 
Table 7.23 ApoStream® System: Specifications
 
Table 7.24 Comparison Between ApoStream® CTC Platform and CELLSEARCH® CTC Platform
 
Table 7.25 ApoCell: Posters / Presentations at Different Conferences
 
Table 7.26 Parsortix™ System: Publications
 
Table 7.27 Parsortix™ System: Posters / Presentations at Different Conferences
 
Table 8.1 Liquid Biopsy Market: Funding Instances, 2011-2017
 
Table 8.2 Liquid Biopsy Market: Types of Funding Instances, 2011-2017
 
Table 9.1 Company Valuation Analysis: Sample Dataset
 
Table 9.2 Company Valuation Analysis: Weighted Average Evaluation
 
Table 9.3 Company Valuation Analysis: Estimated Valuation
 
Table 10.1 Liquid Biopsy: List of Companies Profiled
 
Table 10.2 Biocartis: Portfolio of Liquid Biopsy Tests
 
Table 10.3 Idylla™ ctBRAF Mutation Assay: Features
 
Table 10.4 Idylla™ ctKRAS Mutation Assay: Features
 
Table 10.5 Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay: Features
 
Table 10.6 Biocept: Portfolio of Liquid Biopsy Tests
 
Table 10.7 Biodesix: Funding Instances 
 
Table 10.8 Biodesix: Portfolio of Liquid Biopsy Tests
 
Table 10.9 VeriStrat® Test: Publications
 
Table 10.10 Exosome Diagnostics: Funding Instances
 
Table 10.11 Exosome Diagnostics: Portfolio of Liquid Biopsy Tests
 
Table 10.12 Oncotype SEQ™ Liquid Select Mutation Panel: Clinical Results
 
Table 10.13 Guardant Health: Funding Instances
 
Table 10.14 NeoGenomics Laboratories: Portfolio of Liquid Biopsy Tests
 
Table 10.15 NeoLAB™ HEME: Multiplex Profiles
 
Table 10.16 NeoGenomics Laboratories: Publications
 
Table 10.17 Personal Genome Diagnostics: Funding Instances
 
Table 10.18 Personal Genome Diagnostics: Portfolio of Liquid Biopsy Tests
 
Table 10.19 MetDETECT™: Specifications
 
Table 10.20 QIAGEN: Portfolio of Liquid Biopsy Tests
 
Table 10.21 Q1Aamp® Circulating Nucleic Acid Kit: Specifications
 
Table 10.22 ICEme Kits: Number of Possible COSMIC Mutations and Insertions / Deletions  
 
Table 10.23 Transgenomic: Portfolio of Liquid Biopsy Tests
 
Table 10.24 MX-ICP CRC Analysis: Genes Analyzed and Recommended Treatment Options
 
Table 10.25 MX-ICP Melanoma Analysis: Genes Analyzed and Recommended Treatment Options 
 
Table 10.26 MX-ICP NSCLC Analysis: Genes Analyzed and Recommended Treatment Options
 
Table 10.27 MX-ICP: Single-Gene Liquid Biopsy Tests
 
Table 10.28 Trovagene: Portfolio of Liquid Biopsy Tests
 
Table 10.29 Trovera™ Tests: Posters / Presentations at Different Conferences
 
Table 11.1 Other Non-Invasive Cancer Diagnostics: Market Landscape
 
Table 11.2 Survey Response: Overview of the Participating Companies
 
Table 11.3 Survey Response: Seniority Level of Respondents
 
Table 11.4 Survey Response: Type of Product Portfolio
 
Table 11.5 Survey Response: Type of Products / Services Offered
 
Table 11.6 Survey Response: Type of Application
 
Table 11.7 Survey Response: Availability of the Products
 
Table 11.8 Survey Response: Likely Liquid Biopsy Market Size (2030)
 
Table 11.9 Survey Response: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
 
Table 12.1 Liquid Biopsy for Early Diagnosis: Forecast Assumptions and Data Points
 
Table 12.2 Liquid Biopsy for Patient Monitoring: Forecast Assumptions and Data Points
 
Table 12.3 Liquid Biopsy for Recurrence Monitoring: Forecast Assumptions and Data Points
 
Table 12.4 Key Indications: Forecast Assumptions and Data Points
 
Table 15.1 Worldwide Incidence: Distribution by Type of Cancer
 
Table 15.2 Lung Cancer: Estimated New Cases in 2016 (In Thousands)
 
Table 15.3 Breast Cancer: Estimated New Cases in 2016 (In Thousands)
 
Table 15.4 Colorectal Cancer: Estimated New Cases in 2016 (In Thousands)
 
Table 15.5 Liquid Biopsy Tests: Distribution by Development Stage
 
Table 15.6 Liquid Biopsy Tests: Distribution by Sample Type
 
Table 15.7 Liquid Biopsy Tests: Distribution by Type of Markers Detected
 
Table 15.8 Liquid Biopsy Tests: Distribution by Indication
 
Table 15.9 Liquid Biopsy Tests: Distribution by Type of Application
 
Table 15.10 Liquid Biopsy Tests: Distribution by Leading Players
 
Table 15.11 Liquid Biopsy Market: Cumulative Funding Instances, 2011-2017
 
Table 15.12 Liquid Biopsy Market: Cumulative Funding Amount, 2011-2017 (USD Billion)
 
Table 15.13 Liquid Biopsy Tests: Distribution by Type of Funding Instances, 2011-2017
 
Table 15.14 Liquid Biopsy Tests: Distribution by Total Amount Invested, 2011-2017 (USD Billion)
 
Table 15.15 Leading Players: Distribution by Number of Funding Instances
 
Table 15.16 Company Valuation Analysis: Valuation Ratios, Input Dataset
 
Table 15.17 Biocartis: Annual Revenues, 2012-2016 (EUR Million)
 
Table 15.18 Biocept: Annual Revenues, 2012-2016 (USD Million)
 
Table 15.19 GeneStrat: Clinical Validation Data
 
Table 15.20 Genomic Health: Annual Revenues, 2010-2016 (USD Million)
 
Table 15.21 NeoGenomics Laboratory: Annual Revenues, 2010-2016 (USD Million)
 
Table 15.22 QIAGEN: Annual Revenues, 2010–2016 (USD Billion)
 
Table 15.23 QIAGEN Sales, 2016: Distribution by Business Segments
 
Table 15.24 Transgenomic: Annual Revenues, 2010 – Q1-Q3 2016 (USD Million)
 
Table 15.25 Trovagene: Annual Revenues, 2010–2016 (USD Million)
 
Table 15.26 Survey Analysis: Distribution by Geography
 
Table 15.27 Survey Analysis: Seniority Levels of Respondents
 
Table 15.28 Survey Analysis: Distribution by Type of Product Portfolio
 
Table 15.29 Survey Analysis: Distribution by Type of Products / Services Offered
 
Table 15.30 Survey Analysis: Distribution by Type of Application
 
Table 15.31 Survey Analysis: Distribution by Availability of Products
 
Table 15.32 Survey Analysis: Likely Liquid Biopsy Market Size (2030)
 
Table 15.33 Survey Analysis: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
 
Table 15.34 Liquid Biopsy Market: Distribution of Patient Population into Risk Groups
 
Table 15.35 Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
 
Table 15.36 Non-Invasive Cancer Diagnostics Market (2017-2030): Optimistic Scenario (USD Billion)
 
Table 15.37 Non-Invasive Cancer Diagnostics Market (2017-2030): Conservative Scenario (USD Billion)
 
Table 15.38 Liquid Biopsy Market (2017-2030): Base Scenario (USD Billion)
 
Table 15.39 Liquid Biopsy Market (2017-2030): Optimistic Scenario (USD Billion)
 
Table 15.40 Liquid Biopsy Market (2017-2030): Conservative Scenario (USD Billion)
 
Table 15.41 Liquid Biopsy Market: Share by Application, (USD Billion, %)
 
Table 15.42 Liquid Biopsy Market: Share by Indication, (%)
 
Table 15.43 Liquid Biopsy Market: Share by Type of Marker, (%)
 
Table 15.44 Liquid Biopsy Market: Share by Type of Sample, (%)
 
Table 15.45 Liquid Biopsy Market: Share by Type of Marker, (%)
 
Table 15.46 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
 
Table 15.47 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Optimistic Scenario (USD Billion)
 
Table 15.48 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Conservative Scenario (USD Billion)
 
Table 15.49 Non-Invasive Cancer Diagnostics Market (USD Billion), 2017, 2023 and 2030
 
 
 
The following companies and organizations have been mentioned in the report.
 
  1. 10 MED
  2. 360 Genomics
  3. Abbott
  4. Acadia Woods Partners
  5. Accel Biotech
  6. Accelerate Brain Cancer Cure
  7. AccuraGen
  8. Acecgt Life Science
  9. Acer
  10. Ackermans & van Haaren
  11. Acousys Biodevices
  12. AcuamarkDx
  13. Adaptive Biotechnologies
  14. Addario Lung Cancer Medical Institute (ALCMI)
  15. Admera Health
  16. AdnaGen
  17. Aetna
  18. Affymetrix
  19. Agena Bioscience
  20. Akademiska Hospital
  21. Alexandria Venture Investments
  22. Allegro Diagnostics
  23. Allele Frequency Community
  24. Allen & Company
  25. Alliance Global
  26. Alloy Ventures
  27. Almac Group
  28. Amadix
  29. AME Cloud Ventures
  30. America’s Choice Provider Network
  31. American Association for Cancer Research
  32. American Lung Association
  33. American Society of Clinical Oncology
  34. American Urological Association
  35. AmeriHealth
  36. Amgen
  37. Amplitech
  38. Andreessen Horowitz
  39. Andros Mannenkliniek
  40. ANGLE
  41. Ann Arbor SPARK
  42. Anpac Bio
  43. ApoCell
  44. Apollo Hospital
  45. Appistry
  46. ARCH Venture Partners
  47. Arcus Ventures
  48. Array BioPharma
  49. Artiman Ventures
  50. ARUP Laboratories
  51. Aspire Capital Fund
  52. Asset Management Ventures
  53. Assurant
  54. Astellas Pharma
  55. Astia Angels
  56. AstraZeneca
  57. ATGen
  58. Athena Advisors
  59. Atlantic Cancer Research Institute
  60. Attikon University Hospital
  61. Aurelia Private Equity
  62. Aurora Diagnostics
  63. Aurum Ventures MKI
  64. AVEO Oncology
  65. AVIVA Biosciences
  66. AXON Dx
  67. Ballast Point Ventures
  68. Barts Cancer Institute
  69. Bayer Healthcare
  70. Baylor College of Medicine
  71. BC Biomedical Laboratories
  72. BC Cancer Agency
  73. Becton Dickinson
  74. Benaruca
  75. Betta Pharmaceuticals
  76. BGI Tech Solutions
  77. Bio.be
  78. Biocartis
  79. Biocept
  80. Biodesix
  81. BioFluidica
  82. Biogen
  83. Biognosys
  84. Biohit HealthCare
  85. Biological Dynamics
  86. BioMark Diagnostics
  87. bioMerieux
  88. Bio-Rad
  89. BioSense Medical
  90. Biosensors International
  91. Biotron Healthcare
  92. Biotype Diagnostics
  93. BioVeda
  94. BioVendor
  95. Biovest
  96. Bioyong Technology Company
  97. Birla Sun Life Insurance
  98. Blair Gastroenterology Associates
  99. Blisce
  100. Blue Cross and Blue Shield of Illinois
  101. Blue Cross and Blue Shield of Louisiana
  102. Blue Cross Blue Shield of Michigan
  103. Blue Ridge Capital
  104. Boreal Genomics
  105. Brand Capital
  106. Brandenburg Capital (BFBII)
  107. Breast Care Centre - Jefferson Health
  108. Breathtec Biomedical
  109. Brigham and Women's Hospital
  110. Bristol-Myers Squibb
  111. Cadence Bank
  112. Cahaba Government Benefit Administrators
  113. Cambridge Innovation Capital
  114. Cambridge Oncometrix
  115. Cancer Genetics
  116. Canopus Bioscience
  117. Capio Biosciences
  118. Capital Health Plan
  119. Capital Royalty Partners
  120. CareFirst
  121. Caris Life Sciences
  122. Casdin Capital
  123. Catholic Health Initiatives Centre for Translational Research
  124. CD Ventures
  125. CDBI Partners
  126. CeGaT
  127. CellMax Life
  128. Celsee Diagnostics
  129. Centro di Ricerche Oncologiche di Mercogliano (CROM)
  130. Cerba HealthCare
  131. Charles River Associates
  132. Cigna
  133. Circulogene Theranostics
  134. City of Hope Medical Center
  135. CKM Capital Partners
  136. Claremont Creek Ventures
  137. Clarient
  138. Clearbridge BioMedics
  139. Clearbridge BSA
  140. Clinical and Experimental Pharmacology Group, The University of Manchester
  141. Clinical Genomics
  142. CloudHealth Genomics
  143. Clovis Oncology
  144. CollabRx
  145. College of American Pathologists
  146. Color
  147. Columbia University
  148. Concentra
  149. CORE Diagnostics
  150. COTA Partners
  151. Counsyl
  152. Creatv MicroTech
  153. Crede Capital Group
  154. Cynvenio Biosystems
  155. CytoLumina Technologies
  156. CytoTrack
  157. Dana-Farber Cancer Institute
  158. Data Collective
  159. Datar Genetics
  160. DDL Diagnostic Laboratory
  161. Debiopharm Group
  162. Decheng Capital
  163. Deerfield Capital Management
  164. Department of Biopathology, Institut de Cancérologie de Lorraine (ICL)
  165. Department of Oncology, Vejle Hospital
  166. Department of Urology, Radboud University Medical Center
  167. DermTech
  168. DiaDx
  169. DiagnoCure
  170. Diagnologix
  171. Diagnostica Longwood
  172. Diffusion Capital Partners
  173. Domain Associates
  174. Dr Lal PathLabs
  175. Dr. Rosell Oncology Institute
  176. Drug Response Dx
  177. DSP BlackRock
  178. DT Capital Partners
  179. Dynacare
  180. Eastern Cooperative Oncology Group
  181. Edison Innovation VC Growth Fund
  182. EKF Molecular Diagnostics
  183. Eli Lilly
  184. EmblemHealth
  185. Emerge Venture
  186. EONE-DIAGNOMICS Genome Center
  187. Epic Sciences
  188. Epigenomics
  189. Epistem Pharmacogenomics
  190. Eta Diagnostics
  191. EUREKA
  192. European Medical Network for Translational Research in Ovarian Cancer (EUTROC)
  193. European Research Organization on Genital Infection and Neoplasia (EUROGIN)
  194. European Society for Medical Oncology
  195. Exact Sciences
  196. Exalenz Bioscience
  197. Exosome Diagnostics
  198. Exosome Sciences
  199. Exosomics Siena
  200. Fairview Health Services
  201. Federal Holding and Investment Company
  202. FedMed
  203. Felicis Ventures
  204. Fidelity Investments
  205. First Coast Service Options
  206. Flatiron Health
  207. Flemish Agency for Innovation & Entrepreneurship
  208. Florida Blue
  209. Fluxion Biosciences
  210. Forbion Capital Partners
  211. Formation 8
  212. Fortified Provider Network
  213. Foundation Medicine
  214. Franklin Synergy Bank
  215. Franklin Templeton Investments
  216. Fraunhofer Institute for Cell Therapy and Immunology
  217. Galaxy Health Network
  218. GATC Biotech
  219. GBP Scientific
  220. GE Ventures
  221. Genetic Technologies
  222. Genomac Research Institute
  223. Genomic Health
  224. Genomictree
  225. Genoptix
  226. Genostics
  227. GenSignia
  228. Gentris
  229. Georgetown Lombardi Comprehensive Cancer Center
  230. GILUPI
  231. Goldman Sachs Asset Management
  232. Google Ventures 
  233. GRAIL
  234. Green Pine Capital Partners
  235. Greenwoods Private Equity Funds
  236. Group Health Cooperative
  237. Guardant Health
  238. Hancock Bank
  239. HarlePhil Ventures, Harle Group
  240. Harmony Partners
  241. Health Alliance Plan
  242. Health Canada
  243. Health Care Services Corporation
  244. Health Net
  245. HealthCor Partners Management
  246. Hemosure
  247. Heritage Group
  248. HIFU CLINIC Prostate Cancer Treatment Center 
  249. Highmark
  250. High-Tech Gründerfonds
  251. Hitachi Chemical Diagnostics
  252. Hitachi High-Technologies Corporation
  253. Hologic
  254. Hooper Holmes Health and Wellness
  255. Horizon Blue Cross Blue Shield of New Jersey 
  256. HTG Molecular Diagnostics
  257. Humana
  258. Hygieia Sciences
  259. IBM Watson
  260. iCellate Medical
  261. ICICI Prudential
  262. Illumina
  263. Imperial Innovations
  264. Incyte
  265. Independence BlueCross
  266. IndivuTest
  267. Inivata
  268. Innogene Kalbiotech
  269. Innovation Endeavors
  270. Inserm Transfert
  271. Insight Genetics
  272. Instituto Diagnostico Varelli
  273. Integrated Personalize Medicine
  274. Interpace Diagnostics
  275. Inventures
  276. IPS Genomix
  277. IVDiagnostics
  278. Janssen Diagnostics
  279. Sidney Kimmel Cancer Center, Thomas Jefferson University 
  280. Jennison Associates
  281. Johns Hopkins University School of Medicine
  282. Johnson & Johnson Development Corporation
  283. Johnson & Johnson Innovation
  284. JoyingBio
  285. JP Morgan Chase
  286. Junson Capital
  287. Kadmon Corporation
  288. Kaiser Permanente
  289. Karolinska Institute
  290. KBC Bank
  291. Kearny Venture Partners
  292. KfW Bankengruppe
  293. Khosla Ventures
  294. Kleiner Perkins Caufield & Byers
  295. KMD Biomarker Diagnostics
  296. Kodiak Venture Partners
  297. Koninklijke Philips
  298. Korys
  299. Kotak Mahindra Bank
  300. Lab21
  301. Labco Quality Diagnostics
  302. LabCorp
  303. LabsMD
  304. Lakeshore ArchAngels
  305. Lantern Pharma
  306. LCM Genect
  307. LifeLabs
  308. Lightspeed Venture Partners
  309. Lilly Asia Ventures
  310. Liquid Biotech USA
  311. Livzon Pharmaceutical Group
  312. London Health Sciences Centre 
  313. Louisiana State University
  314. Manipal Group
  315. Martinské bioptické centrum
  316. Massachusetts General Hospital
  317. Massey Cancer Centre
  318. Mayo Clinic
  319. Mayo Medical Laboratory
  320. MD Anderson Cancer Center
  321. MDNA Life Sciences
  322. MDxHealth
  323. MedGenome  
  324. Medical Mutual of Ohio
  325. Medical University of Vienna
  326. MediLabs
  327. MedImmune
  328. MedSIR
  329. MedStar Georgetown University Hospital
  330. MedX Health
  331. MELA Sciences
  332. Memorial Sloan Kettering Cancer Center
  333. Menarini Silicon Biosystems
  334. Menssana Research
  335. Merck
  336. Merrill Lynch
  337. Metabiomics
  338. Metabolomic Technologies
  339. Metabolomx
  340. MetaCell
  341. Michael J. Fox Foundation
  342. Mikro Biyosistemler
  343. Milenia Labs
  344. MiNDERA
  345. Ministry of Health, Labour and Welfare, Japan
  346. Mirati Therapeutics
  347. Miroculus
  348. MiRXES  
  349. MLabs, University of Michigan
  350. Mohr Davidow Ventures
  351. Molecular Pathology Laboratory Network
  352. MolecularMD
  353. Monashee Capital
  354. mtm laboratories
  355. MultiPlan
  356. Multiplicom
  357. Münchner Leukämie Labor (MLL)
  358. Myriad Genetics
  359. Nan Fung Group
  360. Nanjing Kaiyuan Growth Capital Investments
  361. NASA
  362. Natera
  363. National Cancer Institute, US
  364. National Cancer Research Institute, UK
  365. National Comprehensive Cancer Network, US
  366. National Government Services, US
  367. National Institutes of Health, US
  368. Nektar Therapeutics
  369. NEO New Oncology
  370. NeoGenomics Laboratories
  371. Neuberger Berman Group
  372. New Enterprise Associates
  373. New Jersey Economic Development Authority
  374. New Rhein Healthcare
  375. NGen Partners
  376. NGN Capital
  377. NM Genomix
  378. Nodexus
  379. Norgen Biotek
  380. Noridian, 
  381. Palmetto GBA
  382. Northgate Capital
  383. Northwestern University
  384. Novartis
  385. NovioGendix
  386. Novitas Solutions
  387. NuGen
  388. Olivia Newton-John Cancer Centre
  389. Oncimmune
  390. OncoCyte Corporation
  391. OncoDNA
  392. Oncolys Biopharma
  393. OneVentures
  394. OrbiMed Advisors
  395. Ortho Biotech Oncology Research & Development
  396. Owlstone Medical
  397. Oxford Finance Corporation
  398. Pacific Edge
  399. Palapa Ventures
  400. Palex Medical
  401. Pangaea Biotech
  402. Papillon Capital
  403. Participatiemaatschappij Vlaanderen
  404. PathQC
  405. Pathway Genomics
  406. Pejman Mar Ventures
  407. Perelman School of Medicine, University of Pennsylvania
  408. PeriRx
  409. Personal Genome Diagnostics
  410. Pfizer
  411. Pfizer Venture Investments
  412. Phenomenome Discoveries
  413. Philips
  414. Philips Research
  415. Picomole Instruments
  416. Pilot Growth Equity
  417. Pink Lotus Breast Cancer
  418. PMV Tina Fund
  419. PNC Bank
  420. Polaris Partners
  421. Polymedco
  422. PrairieGold Venture Partners
  423. Predicine
  424. PreferredOne
  425. Premier
  426. Prime Genomics
  427. Prime Value Capital Management
  428. Principia Biopharma
  429. Priority Health Michigan
  430. Progenetics
  431. Promega Corporation
  432. Prostate Cancer Foundation
  433. ProXeom
  434. Pulmostics
  435. QIAGEN
  436. Quaker BioVentures
  437. Queen Mary University
  438. Quest Diagnostics
  439. RA Capital Management
  440. RainDance Technologies
  441. Rarecells Diagnostics
  442. RareCyte
  443. Redmile Group
  444. Regenerus Laboratories
  445. Regions Capital Markets
  446. Reliance Capital
  447. Research Genetic Cancer Centre (R.G.C.C.) Group
  448. Resolution Bioscience
  449. Response Genetics
  450. RMI Partners
  451. Robert H. Lurie Comprehensive Cancer Center, Northwestern University
  452. Roche
  453. Roche Venture Fund
  454. Rosemont Seneca Technology Partners
  455. Rosetta Genomics
  456. Roswell Park Cancer Institute
  457. Royal Philips Electronics
  458. SAGA Diagnostics
  459. SAIC-Frederick
  460. SMBRINVEST
  461. Samsung Medical Center
  462. San Antonio Military Medical Center
  463. Sanomics
  464. Sarah Cannon Research Institute (SCRI)
  465. ScheBo Biotech
  466. ScreenCell
  467. Seaside National Bank and Trust
  468. Sectoral Asset Management
  469. Selah Genomics
  470. Sequenom
  471. Sequoia Capital
  472. Shanghai Zhangjiang Science & Technology Investment Corporation (ZJSTIC)
  473. Siemens Healthcare Diagnostics
  474. Silicon Valley Bank
  475. SIMSYS
  476. Singlera Genomics
  477. Singulex
  478. Sividon Diagnostics
  479. SkyDeck
  480. Skyline Diagnostics
  481. Société Régionale d'Investissement de Wallonie
  482. Sofinim
  483. Sofinnova Ventures
  484. Sorgente Genetica
  485. SouthGenetics
  486. Southwest Oncology Group
  487. Spanish Ministry of Economy and Competitiveness (MINECO)
  488. Spectrum 28
  489. SPRING Seed Capital
  490. SRI International
  491. St. Louis Arch Angels
  492. StableBody Technologies
  493. Stanford-StartX Fund
  494. State Bank of India
  495. Strand Life Sciences
  496. STRATA Skin Sciences
  497. Stratose
  498. Streck
  499. Sungent Bioventure
  500. Sutter Hill Ventures
  501. SYGNIS
  502. Synlab Group
  503. Syno Capital
  504. Sysmex Corporation
  505. Sysmex Inostics
  506. T Rowe Price
  507. Takeda Pharmaceuticals
  508. Technion-Israel Institute of Technology
  509. Telegraph Hill Partners (THP)
  510. TEM Research
  511. Temasek Holdings
  512. Teneovita Medical Innovations
  513. Teva Pharmaceuticals
  514. The eNose Company
  515. The European Health Centre Innovation (EHC Innovation)
  516. The Huntington National Bank
  517. The Institute of Cancer Research
  518. The Pancreatic Cancer Action Network
  519. The University of Manchester
  520. The University of Michigan Comprehensive Cancer Center
  521. The Wistar Institute
  522. Therawis Diagnostics
  523. Thermo Fisher Scientific
  524. Third Kind Venture Capital
  525. Third Rock Ventures
  526. Third Security
  527. Thomas Jefferson University
  528. Three Rivers Provider Network
  529. thromboDx
  530. Tiger Management
  531. Tokai Pharmaceuticals
  532. Transgenomic
  533. Trovagene
  534. Tumor Bank Ovarian Cancer Network
  535. Ucare
  536. United HealthCare
  537. UnitedHealth Group
  538. Universitätsklinikum Knappschaftskrankenhaus Bochum
  539. University Hospital Brussels
  540. University Medical Centre Hamburg-Eppendorf
  541. University of Athens
  542. University of British Columbia
  543. University of California, Los Angeles
  544. University of California, San Diego
  545. University of California, San Francisco
  546. University of Colorado, Anschutz Medical Campus
  547. University of Duisburg-Essen
  548. University of Dusseldorf
  549. University of Melbourne
  550. University of Michigan
  551. University of Pennsylvania
  552. University of Rochester Medical Center
  553. University of Southern California (USC) Norris Comprehensive Cancer Centre
  554. University of Southern Denmark
  555. University of Texas
  556. Uppsala BIO
  557. US Oncology Research (USOR)
  558. US Preventive Services Task Force 
  559. Valiance
  560. Vall d'Hebron Institute of Oncology
  561. Vancouver Prostate Centre
  562. Velox Biosystems
  563. Ventana Medical Systems
  564. Veridex
  565. Vertex Venture Holdings
  566. Viatar CTC Solutions
  567. Vinsovier
  568. Virginia Commonwealth University
  569. Vitatex
  570. VolitionRx
  571. Vortex Bioscience
  572. VU University Medical Center
  573. VWR International
  574. VyCAP
  575. WaveSense
  576. Wellcome Trust Sanger Institute
  577. Wellmark Blue Cross Blue Shield
  578. Wells Fargo Securities
  579. Wilmot Cancer Intitute, Uiverity of Rochester Medical Center
  580. Windham Venture Partners
  581. Wisconsin Physician Services
  582. Woodford Patient Capital Trust
  583. Wren Laboratories
  584. Yale University
  585. Yissum Research Development Company

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security